Close Icon We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Products:

Pharma Consulting

Close Icon

Hot topics

Thought leadership

Research and development strategy

Close Icon

Events

Conferences 2019

Awards

Upcoming Webinars

Webinar recordings

Close Icon

Global Search Configuration

Search Site Products & Services
Close Icon

Search by Keyword

Focus
Needs

Pharmaceutical intelligence for consultancies

Focus on your clients and expand your business opportunities. We’ll help you build a complete picture of the rapidly changing pharmaceutical market with our insight and expertise.

Your trusted pharma partner

With the pharma and healthcare sector facing increasing challenges, your clients rely more than ever on independent intelligence. Pharma Intelligence will help you make smart decisions and stay ahead of a fast changing market.

What we offer

As the trusted partner of the top 50 pharmaceutical companies and 10 contract research organizations, our wide range of solutions cover early phase, clinical R&D, portfolio and strategy, regulatory and commercial planning and analysis.

We cover the life sciences business from drug and device discovery and development to regulatory approval, and drug reimbursement to lifecycle management. And we give you access to past, current and future trends and analysis.

How it helps

Whether you’re working on your next business pitch, engaging on a project for an existing client or working on due diligence for a proposed merger or acquisition; our pharmaceutical intelligence helps you meet the demands of dynamic markets and changing customer needs, with:

Expert analysis of key pharma sectors
In-depth knowledge from drug discovery to market access
Global coverage including digital health, R&D, and emerging markets
Precise analysis and data
Customized reports

Our unique strengths

Understand your clients’ world

Gain a comprehensive understanding of the global pharma market with our complete coverage.

Stay on top of the details

We’ll keep you in touch with complex regulatory and pricing and reimbursement issues.

Think ahead

Respond to market events, identify opportunities and anticipate changes by tracking drug pipelines, patent expiration and commercial activities influencing the landscape.

Deliver tailored solutions

Use our data and insight to create solutions to suit your clients’ needs.

Benefit from a dedicated service

Our services come with dedicated client service and analyst support.

View more
View Less

Relevant products

Awareness

Key benefits:

Direct access to your target Pharma audience
Multi or single channel campaigns
Effective reporting

Thought leadership

Key benefits:

Build brand credibility
Generate Leads
Effective reporting

Our popular solutions

Key benefits:

Direct access to your target Pharma audience
A cohesive marketing campaign
Effective reporting

View all content

Generics Bulletin

Corporate Strategies of the biggest Generics and Biosimilar players

17 Sep 2019

Understand the latest Corporate Strategies of the biggest Generics and Biosimilar players.

Topic Business strategies

Single report
Scrip

Inclisiran’s Safety Data Suggest Game-Changing Potential In PCSK9 Market

By Joseph Haas 11 Sep 2019

The Medicines Co. unveiled Phase III safety data for inclisiran showing safety and tolerability comparable to placebo and efficacy in line with the PCSK9 inhibitor class – which should be the reassurance it needs for the oral agent.

Topic Drug development landscape Drug review

View article
Scrip

Interview: AstraZeneca’s Pangalos on Landmark DAPA-HF Resultsv

By Eleanor Malone 11 Sep 2019

AstraZeneca’s head of R&D spoke to Scrip about the outstanding results for dapagliflozin in heart failure regardless of diabetes status.

Topic Company analysis Diabetes

View article
Scrip

Anima Biotech Lighting The Way In Protein Translation

By Jo Shorthouse 10 Sep 2019

Emerging Company Profile: With a new partner in Eli Lilly, Anima Biotech and its disruptive technology that controls protein translation is starting to make waves as it urges the industry to see the light.

Topic Clinical trials

View article
Generics Bulletin

Executive and market moves interviews for exclusive insider knowledge

04 Sep 2019

Get in the side track on the Generics market with executive and market-moves interviews for exclusive insider knowledge.

Topic Business strategies

Single report
Datamonitor Healthcare

Reimbursement and Payer Management of Immune Checkpoint Inhibitors

03 Sep 2019

As immune checkpoint inhibitors continue to gain approvals in expanded patient populations, payers express concern surrounding the potential budget impact of the drug class. Considering the high costs of these treatments in comparison to standard chemotherapy, HTA and reimbursement agencies stress the requirement for solid survival data and highlight that price will be a major factor during negotiations

Topic Drug review

Single report
Datamonitor Healthcare

NASH Disease Coverage Extract

16 Aug 2019

Datamonitor Healthcare recently surveyed 60 gastroenterologists in the US and five major EU markets after the approval of the first disease-specific therapies for the treatment of non-alcoholic steatohepatitis (NASH). The market for these treatments will exceed $21bn in 2027.

Topic Drug development landscape Diseases

Single report
Generics Bulletin

Hikma Snaps Up Insys Sprays As Part Of US Drive Towards Differentiation

By Aidan Fry 15 Aug 2019

By acquiring global rights to epinephrine and naloxone nasal spray candidates from Insys, Hikma is following its strategy of moving its non-injectable Generics business segment in the US towards differentiated products.

Topic Business strategies

View article
Scrip

An AdComm After All: Amarin's Vascepa Labeling Update Now Delayed By FDA

By Mandy Jackson 15 Aug 2019

The US FDA informed the company it will convene an advisory committee meeting to review the REDUCE-IT sNDA for the proprietary fish oil pill, delaying the approval by at least three months and surprising investors.

Topic FDA Drug approval

View article
Scrip

Taltz Tops Tremfya In Head-To-Head Psoriasis Study On Complete Skin Clearance

By Jessica Merrill 15 Aug 2019

Lilly's IL-17A inhibitor ixekizumab outperformed J&J's IL-23 inhibitor guselkumab on achieving complete skin clearance in moderate-to-severe psoriasis patients at 12 weeks in a head-to-head trial.

Topic Clinical trials

View article
Pink Sheet

Novartis' Zolgensma Had Manipulated Data In Application, US FDA Says

By Derrick Gingery 14 Aug 2019

Gene therapy should remain on the market, FDA says, but Novartis could face civil or criminal penalties. Firm knew of problems before approval.

Topic FDA Company analysis

View article
Generics Bulletin

Chirag Patel And Chintu Patel Return As Co-CEOs Of Amneal

By David Wallace 14 Aug 2019

Chirag Patel and Chintu Patel have returned to being co-CEOs of Amneal, just over a year after the firm completed its merger with Impax. Rob Stewart – who was president and CEO of Amneal – and executive chairman Paul Bisaro have resigned from the roles.

Topic Company analysis

View article
Scrip

Oncology Market Leaders Maintain Their Upper Hand

By Jessica Merrill 14 Aug 2019

Drugs like Ibrance and Lynparza show that in the cancer market, it can be hard for new entrants to catch early standouts.

Topic Drug development landscape Drug review

View article
Scrip

The Chinese Pharma Market: Insights in turbulent times

12 Aug 2019

With the continuation of the US-China trade standoff, the rapid increase in R&D costs and a gruelling centralized bidding process, foreign pharma firms have a lot on their plates in China. Gain insight on these key challenges through this Scrip article pack

Topic Business strategies

Single report
Pink Sheet

The Stakes Are High So Get It Right: CHMP Oral Explanations & FDA AdComs

By Neena Brizmohun 09 Aug 2019

The stakes are extremely high for companies called before EU or US regulators and scientific experts to answer queries about their new drug applications at the later stages of the review process. How they perform is critical. Consultant Kate Dion has a raft of helpful tips for companies facing this daunting situation. Neena Brizmohun reports.

Topic Drug approval

View article

Latest headlines

Scrip

20 Sep 2019

Pipeline Watch: Phase II Starts In Hearing Loss, Type 1 Diabetes

Link
Scrip

20 Sep 2019

Gene Profiling Identifies Drugs For Childhood Cancers But Access A Problem

Link
Pink Sheet

20 Sep 2019

Longer Medicine Supply Delays Expected In No-Deal Brexit

Link
Pink Sheet

20 Sep 2019

Recent And Upcoming FDA Advisory Committee Meetings

Link
Scrip

20 Sep 2019

Emmaus Fumes After EMA Rejects Sickle Cell Drug Again

Link
Scrip

20 Sep 2019

Brighter News For Varlitinib As Results In Tough Cancer Type Encourage ASLAN

Link
Pink Sheet

19 Sep 2019

Keep It Simple: EU Consults On Future Design Of EMA’s Fee System

Link
Pink Sheet

19 Sep 2019

Rare Disease Cures Accelerator Expected To Drive Lots Of Development – Eventually

Link
Pink Sheet

19 Sep 2019

Clinical Outcome Assessments To Be Developed Under US FDA Grants

Link
Pink Sheet

19 Sep 2019

Industry Still Awaiting Clarity On Brexit Supply Chain Arrangements

Link
Pink Sheet

19 Sep 2019

Part D Out-Of-Pocket Cap Would Be $2,000 In House Drug Pricing Bill

Link
Pink Sheet

19 Sep 2019

House Democrats Launch Price Negotiation Push: Extreme Plan Assures Strong Opposition

Link
Scrip

19 Sep 2019

ARIBIO Counts On Multi-Modal Drug For Alzheimer's And Vascular Dementia

Link
Scrip

19 Sep 2019

What’s At Stake As China Expands '4+7' Scheme: An Infographic Snapshot

Link
Scrip

19 Sep 2019

Boundless Bio Launches With $46m And Novel Oncology Focus On Extrachromosomal DNA

Link

Next steps

Request a live demo

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Request a free demo

How can we help you?

Our team is always happy to hear from you. Please call us at:

US Toll-Free : +1 888 670 8900
US Toll : +1 908 547 2200
UK & Europe : +44 (20) 337 73737
Australia : +61 2 8705 6907
Japan : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Pharmaceutical intelligence for consultancies

Your trusted pharma partner

Our unique strengths

Understand your clients’ world

Stay on top of the details

Think ahead

Deliver tailored solutions

Benefit from a dedicated service

Relevant products

Below are the Product List

Awareness

Thought leadership

Our popular solutions

Pharma Intelligence latest insights

Latest headlines

Next steps

This is Contactus Section

Request a live demo

How can we help you?

Pharma Report Store